Management of Doxepin-Induced Bradycardia
Immediately discontinue doxepin if symptomatic bradycardia develops, as this is a medication-induced reversible cause that requires elimination of the offending agent as first-line management.
Initial Assessment and Stabilization
When a patient on doxepin presents with bradycardia, your first priority is determining whether the bradycardia is causing symptoms or hemodynamic compromise. Look specifically for:
- Signs of poor perfusion: acute altered mental status, ischemic chest discomfort, acute heart failure, hypotension, or other signs of shock 1
- Heart rate: typically <50 bpm if clinically significant 1
- 12-lead ECG: to identify the specific rhythm disturbance and conduction abnormalities 2
The FDA label for doxepin explicitly lists cardiovascular effects including hypotension, hypertension, and tachycardia as adverse reactions, though bradycardia can occur particularly in overdose situations or with drug interactions 3. Importantly, tricyclic antidepressants like doxepin can cause cardiac dysrhythmias and conduction abnormalities 3.
Immediate Management Algorithm
Step 1: Discontinue Doxepin
The 2018 ACC/AHA/HRS Bradycardia Guideline (Class I recommendation) states that patients presenting with symptomatic bradycardia secondary to a reversible cause should first be managed by directing therapy at eliminating or mitigating the offending condition 4, 5. Doxepin is a clear reversible cause and must be stopped immediately.
Step 2: Pharmacologic Intervention for Symptomatic Bradycardia
If the patient has symptomatic bradycardia with signs of instability:
Atropine remains first-line therapy:
- Dose: 0.5-1 mg IV, may repeat every 3-5 minutes to maximum total dose of 3 mg 2, 1, 2, 6, 5
- Critical caveat: Doses <0.5 mg may paradoxically worsen bradycardia 2
- Atropine is reasonable for symptomatic sinus node dysfunction (Class IIa) 5
Important limitation with doxepin: Research shows that physostigmine and atropine did not modify doxepin's cardiotoxic effects in animal models, suggesting the anticholinergic property may not be the primary mechanism of severe cardiotoxicity 7. However, atropine should still be attempted as per guidelines for symptomatic bradycardia.
Step 3: If Atropine Fails
Alternative agents (Class IIa/IIb recommendations):
- Dopamine infusion: 5-20 mcg/kg/min IV, starting at 5 mcg/kg/min, increasing by 5 mcg/kg/min every 2 minutes 1, 5
- Epinephrine infusion: 2-10 mcg/min IV or 0.1-0.5 mcg/kg/min IV titrated to effect 1, 5
- Transcutaneous pacing (TCP): Reasonable if medications fail (Class IIa) 2, 1, 2, 6
The 2025 AHA Guidelines note that whether to use TCP, epinephrine, dopamine, or other vasoactive agents depends on clinician experience and available resources 1.
Step 4: Transvenous Pacing
If the patient does not respond to drugs or TCP, transvenous pacing is probably indicated (Class IIa) 6. This is particularly important as a bridge to definitive treatment while doxepin is metabolized and cleared 1.
Critical Pitfalls to Avoid
Do not use beta-blockers: Research demonstrates that beta-blockers dose-dependently enhance doxepin-induced bradycardia and can accelerate death in animal models 7. This is a dangerous combination.
Monitor for conduction blocks: Doxepin can cause various degrees of AV block 3. If high-degree AV block (Mobitz type II or third-degree) develops, atropine may be ineffective and immediate pacing should be considered 2.
Watch for QRS widening: Tricyclic antidepressant toxicity manifests with QRS prolongation. A maximal limb-lead QRS duration ≥0.10 seconds indicates severity of overdose 3. Sodium bicarbonate should be used to maintain serum pH 7.45-7.55 if this occurs.
Avoid doses of atropine <0.5 mg: These can paradoxically worsen bradycardia 2, 8, 2.
Consider drug interactions: Doxepin is metabolized by CYP2D6, and inhibitors can increase plasma concentrations 3. Concurrent use of other rate-limiting medications (calcium channel blockers, other beta-blockers) significantly increases bradycardia risk 9, 10.
Monitoring and Follow-up
- Continuous cardiac monitoring for at least 6 hours after presentation, extended if any signs of toxicity 3
- Serial ECGs to monitor QRS duration and rhythm
- Hemodynamic monitoring until heart rate normalizes
- Expect improvement within 48 hours of doxepin discontinuation based on similar medication-induced bradycardia cases 11
Long-term Management
Once stabilized, do not restart doxepin. Consider alternative antidepressants without significant cardiac conduction effects. The patient should be counseled about the risk and provided with alternative treatment options for their underlying psychiatric condition 3.